Martingale Asset Management L P acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 16,033 shares of the specialty pharmaceutical company’s stock, valued at approximately $327,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. PNC Financial Services Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 233.9% in the first quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock valued at $44,000 after buying an additional 1,558 shares during the last quarter. Prospera Financial Services Inc bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at about $194,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at about $187,000. Bank of Montreal Can raised its holdings in shares of Collegium Pharmaceutical by 9.2% in the first quarter. Bank of Montreal Can now owns 11,850 shares of the specialty pharmaceutical company’s stock valued at $239,000 after buying an additional 1,001 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Collegium Pharmaceutical by 23.6% in the first quarter. Envestnet Asset Management Inc. now owns 16,028 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 3,058 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on COLL. StockNews.com cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, May 19th. HC Wainwright lowered Collegium Pharmaceutical to a “neutral” rating in a research report on Monday, August 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.25.
Collegium Pharmaceutical Price Performance
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last posted its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($1.19). The company had revenue of $123.55 million for the quarter, compared to analyst estimates of $122.63 million. Collegium Pharmaceutical had a negative return on equity of 2.12% and a negative net margin of 11.24%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 4.21 EPS for the current year.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- Get a free copy of the StockNews.com research report on Collegium Pharmaceutical (COLL)
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.